A new case report and review, published on February 6, 2026, in Oncotarget, Volume 17, details a specific instance of a woman developing acute lymphoblastic leukemia and lymphoblastic lymphoma after receiving an mRNA COVID-19 vaccine. Authored by an international research team led by Patrizia Gentilini and Panagis Polykretis, the report reviews existing literature and discusses potential immune-related mechanisms that might connect mRNA vaccines to blood cancers, while emphasizing that a definitive cause-and-effect relationship has not been established.
The authors recommend further investigation and long-term safety monitoring of mRNA vaccine technologies.
Publication Details
The report, titled "Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms," was published in Volume 17 of Oncotarget. The research team included first author Patrizia Gentilini and corresponding author Panagis Polykretis, affiliated with the "Allineare Sanità e Salute" Foundation and the Independent Medical Scientific Commission (CMSi) in Milano.
Detailed Case Study
The report presents the case of a 38-year-old woman who developed acute lymphoblastic leukemia and lymphoblastic lymphoma. According to the report, she experienced immune-related symptoms the day after receiving her second Pfizer-BioNTech COVID-19 mRNA vaccine dose. Within months of this vaccination, she was diagnosed with an aggressive blood cancer affecting early-stage lymphocytes.
The woman achieved complete remission following chemotherapy but subsequently experienced a central nervous system relapse, which led to a stem cell transplant. The authors of the report suggest that this sequence of events warrants consideration regarding a potential contribution of a vaccine-induced immune response to the development of the disease.
Broader Context and Proposed Mechanisms
To provide broader context for their observations, the authors reviewed other documented cases of similar cancers, including lymphomas, leukemias, and other haematopoietic disorders, that were reported after COVID-19 vaccination. These instances, according to the report, often showed symptom onset shortly after vaccination. While acknowledging the rarity of such occurrences, the authors stated that these patterns merit closer study.
The report discusses several potential biological mechanisms that the authors propose could link mRNA vaccines to blood cancers. These include:
- Immune suppression.
- Increased inflammation.
- Interference with cancer-protective proteins, such as p53, potentially related to vaccine components.
Concerns were also highlighted regarding lipid nanoparticles, which are used to deliver the vaccine. The authors noted that these nanoparticles may circulate beyond the injection site to other organs, including the bone marrow. They proposed that changes in immune signaling, antibody responses, and genetic material could, under certain conditions, potentially create an environment favorable for cancer development in susceptible individuals.
Limitations and Call for Further Research
The authors explicitly stated that the case report does not establish a definitive cause-and-effect relationship between mRNA vaccination and the observed cancers.
They emphasized that the potential carcinogenic risk associated with these technologies, acknowledged within the gene therapy field, requires investigation based on the medical principle of "primum non nocere" (first, do no harm).
The report concludes that while the presented case does not prove causation, it contributes to existing observations that suggest a need for further study into potential immune disturbances from mRNA vaccines. The authors stressed the importance of continued long-term safety monitoring for mRNA vaccine technologies, particularly as their applications expand, to inform public health decisions and maintain confidence in vaccine programs.